Mutations in THSD7B have the potential to suppress cell death-related signaling activity while promoting the upregulation of invasion and metastasis-related pathways and downregulating immune response pathways, thereby impacting SCLC patient prognosis.[14] The THSD7B rs13405020 SNP is also known to be related to prognostic outcomes in individuals with NSCLC.[15] Protein interaction analyses have demonstrated that THSD7B is capable of interacting with both SPON family proteins as well as THBS1. The gene discussed is THSD7B; the disease is non-small cell lung carcinoma.